IP Library › Granted Patent US 12,257,286
Granted Patent B2
US 12,257,286 · App. 17/288,212 · Granted Mar 25, 2025

Methods and materials for treating cancer

Inventors: Saad J. Kenderian (Rochester, MN); Neil E. Kay (St. Louis Park, MN); Michelle J. Cox (Rochester, MN); Fabrice Lucien-Matteoni (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
A61K38/1774A61K39/4611A61K39/4631A61K39/464412A61P35/02A61K2239/38A61K2239/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,257,286
App. No.
17/288,212
Granted
Mar 25, 2025
Kind
B2
Abstract

This document relates to methods and materials involved in treating mammals having a cancer (e.g., a cancer having one or more CD19 positive extracellular vesicles (EVs) and/or one or more small EVs in the tumor microenvironment). For example, methods of treating a mammal having a blood cancer including one or more CD19 positive EVs and/or one or more small EVs in the blood by administering one or more cancer immunotherapies (e.g., one or more chimeric antigen receptor (CAR) T-cell therapies) to the mammal are provided.

Claims (11)

1. A method for treating a mammal having cluster of differentiation 19 (CD19) positive (CD19 + ) cancer, wherein said method comprises:

(a) assessing extracellular vesicles (EVs) of a tumor microenvironment of said cancer to identify said mammal as being either a mammal having EVs that are CD19 + or a mammal having EVs that are CD19 negative (CD19 − );

(b) identifying said mammal as being said mammal having EV that are CD19 − ; and

(c) administering a CD19 CAR T-cell therapy to said mammal identified in said step (b).

2. The method of claim 1 , wherein said mammal is a human.

3. The method of claim 1 , wherein said cancer is a blood cancer, and wherein said blood cancer is selected from the group consisting of a multiple myeloma, a diffuse small B cell lymphoma, an acute lymphoblastic leukemia, a chronic lymphocytic leukemia, a Hodgkin's lymphoma, a non-Hodgkin's lymphoma, and a T-cell lymphoma.

4. The method of claim 3 , wherein said cancer is a chronic lymphocytic leukemia.

5. A method for treating a mammal having CD19 + cancer, wherein said method comprises administering a CD19 CAR T-cell therapy to a mammal identified as being a mammal having EVs in a tumor microenvironment that are CD19 as compared to being a mammal having EVs in said tumor microenvironment that are CD19 + .

6. The method of claim 5 , wherein said mammal is a human.

7. The method of claim 5 , wherein said cancer is a blood cancer, and wherein said blood cancer is selected from the group consisting of a multiple myeloma, a diffuse small B cell lymphoma, an acute lymphoblastic leukemia, a chronic lymphocytic leukemia, a Hodgkin's lymphoma, a non-Hodgkin's lymphoma, and a T-cell lymphoma.

8. The method of claim 7 , wherein said cancer is a chronic lymphocytic leukemia.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2021
From: KENDERIAN, SAAD J.; KAY, NEIL E.; COX, MICHELLE J.; LUCIEN-MATTEONI, FABRICE
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 056738/0375 →
Continuity (2)
Provisional Application 62753662 · Oct 31, 2018
Related Publication 20210401886A1 · Dec 30, 2021
References Cited (400)
US 3687808A · Merigan, Jr. et al. · 1972 [cited by applicant]
US 4034074A · Miles · 1977 [cited by applicant]
US 4036945A · Haber · 1977 [cited by applicant]
US 4098876A · Piasio et al. · 1978 [cited by applicant]
US 4233402A · Maggio et al. · 1980 [cited by applicant]
US 4257774A · Richardson et al. · 1981 [cited by applicant]
US 4272398A · Jaffe · 1981 [cited by applicant]
US 4331647A · Goldenberg · 1982 [cited by applicant]
US 1376110A · David et al. · 1983 [cited by applicant]
US 4469863A · Ts'o et al. · 1984 [cited by applicant]
US 4650764A · Temin et al. · 1987 [cited by applicant]
US 4769330A · Paoletti et al. · 1988 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4861627A · Mathiowitz et al. · 1989 [cited by applicant]
US 4861719A · Miller · 1989 [cited by applicant]
US 4925673A · Steiner et al. · 1990 [cited by applicant]
US 4935496A · Kudo · 1990 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 4980289A · Temin et al. · 1990 [cited by applicant]
US 4987071A · Cech et al. · 1991 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 5124263A · Temin et al. · 1992 [cited by applicant]
US 5155020A · Paoletti · 1992 [cited by applicant]
US 5155027A · Sledziewski et al. · 1992 [cited by applicant]
US 5175099A · Wills · 1992 [cited by applicant]
US 5204243A · Paoletti · 1993 [cited by applicant]
US 5214136A · Lin et al. · 1993 [cited by applicant]
US 5218105A · Cook et al. · 1993 [cited by applicant]
US 5225336A · Paoletti · 1993 [cited by applicant]
US 5225538A · Capon et al. · 1993 [cited by applicant]
US 5235033A · Summerton et al. · 1993 [cited by applicant]
US 5240846A · Collins et al. · 1993 [cited by applicant]
US 5254678A · Haseloff et al. · 1993 [cited by applicant]
US 5278056A · Bank et al. · 1994 [cited by applicant]
US 5284656A · Platz et al. · 1994 [cited by applicant]
US 5296347A · LaMotte, III · 1994 [cited by applicant]
US 5391682A · Ogawa et al. · 1995 [cited by applicant]
US 5451569A · Wong et al. · 1995 [cited by applicant]
US 5502167A · Waldmann et al. · 1996 [cited by applicant]
US 5521288A · Linsley et al. · 1996 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5558864A · Bendig et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5567584A · Sledziewski et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5596086A · Matteucci et al. · 1997 [cited by applicant]
US 5639641A · Pedersen et al. · 1997 [cited by applicant]
US 5674704A · Goodwin et al. · 1997 [cited by applicant]
US 5675848A · Kappel · 1997 [cited by applicant]
US 5693493A · Robinson et al. · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5698417A · Robinson et al. · 1997 [cited by applicant]
US 5705154A · Dalie et al. · 1998 [cited by applicant]
US 5714147A · Capon et al. · 1998 [cited by applicant]
US 5733743A · Johnson et al. · 1998 [cited by applicant]
US 5750078A · Shitara et al. · 1998 [cited by applicant]
US 5750375A · Sledziewski et al. · 1998 [cited by applicant]
US 5750666A · Caruthers et al. · 1998 [cited by applicant]
US 5770403A · Dalie et al. · 1998 [cited by applicant]
US 5843725A · Sledziewski et al. · 1998 [cited by applicant]
US 5861310A · Freeman et al. · 1999 [cited by applicant]
US 5874240A · Ni et al. · 1999 [cited by applicant]
US 5928893A · Kang et al. · 1999 [cited by applicant]
US 5942607A · Freeman et al. · 1999 [cited by applicant]
US 6018026A · Sledziewski et al. · 2000 [cited by applicant]
US 6210669B1 · Aruffo et al. · 2001 [cited by applicant]
US 6291212B1 · Sledziewski et al. · 2001 [cited by applicant]
US 6291646B1 · Sledziewski · 2001 [cited by applicant]
US 6297008B1 · Okamoto et al. · 2001 [cited by applicant]
US 6300099B1 · Sledziewski et al. · 2001 [cited by applicant]
US 6303121B1 · Kwon · 2001 [cited by applicant]
US 6323323B1 · Sledziewski et al. · 2001 [cited by applicant]
US 6355779B1 · Goodwin et al. · 2002 [cited by applicant]
US 6423885B1 · Waterhouse et al. · 2002 [cited by applicant]
US 6458934B1 · Hong et al. · 2002 [cited by applicant]
US 6630575B2 · Coyle et al. · 2003 [cited by applicant]
US 6635750B1 · Coyle et al. · 2003 [cited by applicant]
US 6740493B1 · Long et al. · 2004 [cited by applicant]
US 6743619B1 · Tang et al. · 2004 [cited by applicant]
US 6803192B1 · Chen · 2004 [cited by applicant]
US 6891030B2 · Chen · 2005 [cited by applicant]
US 6919193B2 · Tang et al. · 2005 [cited by applicant]
US 6943150B1 · Altieri · 2005 [cited by applicant]
US 6965018B2 · Mikesell et al. · 2005 [cited by applicant]
US 7030219B2 · Pardoll et al. · 2006 [cited by applicant]
US 7029674B2 · Carreno et al. · 2006 [cited by applicant]
US 7122351B2 · Moore et al. · 2006 [cited by applicant]
US 7279567B2 · Mikesell et al. · 2007 [cited by applicant]
US 7358354B2 · Mikesell et al. · 2008 [cited by applicant]
US 7368531B2 · Rosen et al. · 2008 [cited by applicant]
US 7381794B2 · Moore et al. · 2008 [cited by applicant]
US 7414122B2 · Fox et al. · 2008 [cited by applicant]
US 7432059B2 · Freeman et al. · 2008 [cited by applicant]
US 7432062B2 · Coyle · 2008 [cited by applicant]
US 7432351B1 · Chen · 2008 [cited by applicant]
US 7449300B2 · Chen et al. · 2008 [cited by applicant]
US 7560540B2 · Pardoll et al. · 2009 [cited by applicant]
US 7563869B2 · Honjo et al. · 2009 [cited by applicant]
US 7582439B2 · Cory et al. · 2009 [cited by applicant]
US 7595048B2 · Honjo et al. · 2009 [cited by applicant]
US 7651686B2 · Chen et al. · 2010 [cited by applicant]
US 7709214B2 · Freeman et al. · 2010 [cited by applicant]
US 7723479B2 · Mikesell et al. · 2010 [cited by applicant]
US 7794710B2 · Chen et al. · 2010 [cited by applicant]
US 7892540B2 · Chen et al. · 2011 [cited by applicant]
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 8039589B1 · Chen · 2011 [cited by applicant]
US 8053414B2 · Pardoll et al. · 2011 [cited by applicant]
US 8053558B2 · Pardoll et al. · 2011 [cited by applicant]
US 8163550B2 · Chen et al. · 2012 [cited by applicant]
US 8268635B2 · Ferrante et al. · 2012 [cited by applicant]
US 8273861B2 · Chen · 2012 [cited by applicant]
US 8383405B2 · Orme · 2013 [cited by applicant]
US 8460927B2 · Chen · 2013 [cited by applicant]
US 8518409B2 · Orme · 2013 [cited by applicant]
US 8772026B2 · Chen et al. · 2014 [cited by applicant]
US 8901120B2 · Bearss et al. · 2014 [cited by applicant]
US 8981063B2 · Chen · 2015 [cited by applicant]
US 9302005B2 · Dong et al. · 2016 [cited by applicant]
US 9534058B2 · Stull et al. · 2017 [cited by applicant]
US 9598491B2 · Ahmed et al. · 2017 [cited by applicant]
US 9730988B2 · Ince et al. · 2017 [cited by applicant]
US 11246890B2 · Lin et al. · 2022 [cited by applicant]
US 11419898B2 · Lu et al. · 2022 [cited by applicant]
US 20010010134A · Rosen et al. · 2001 [cited by applicant]
US 20020076409A1 · March et al. · 2002 [cited by applicant]
US 20020091246A1 · Pardoll et al. · 2002 [cited by applicant]
US 20020095024A1 · Mikesell et al. · 2002 [cited by applicant]
US 20020106730A1 · Coyle et al. · 2002 [cited by applicant]
US 20020107363A1 · Fox et al. · 2002 [cited by applicant]
US 20020110836A1 · Freeman et al. · 2002 [cited by applicant]
US 20020119121A1 · Vitiello et al. · 2002 [cited by applicant]
US 20020160395A1 · Altieri et al. · 2002 [cited by applicant]
US 20020160973A1 · Pero et al. · 2002 [cited by applicant]
US 20020164600A1 · Freeman et al. · 2002 [cited by applicant]
US 20020168719A1 · Kwon · 2002 [cited by applicant]
US 20020177551A1 · Terman · 2002 [cited by applicant]
US 20030039653A1 · Chen et al. · 2003 [cited by applicant]
US 20030142359A1 · Bean et al. · 2003 [cited by applicant]
US 20030171551A1 · Rosenblatt et al. · 2003 [cited by applicant]
US 20030208058A1 · Fiscella et al. · 2003 [cited by applicant]
US 20030223989A1 · Pluenneke · 2003 [cited by applicant]
US 20030232323A1 · Freeman et al. · 2003 [cited by applicant]
US 20040109847A1 · Chen et al. · 2004 [cited by applicant]
US 20040180047A1 · Chen · 2004 [cited by applicant]
US 20040247563A1 · Lynch et al. · 2004 [cited by applicant]
US 20050013811A1 · Chen et al. · 2005 [cited by applicant]
US 20050228170A1 · Fox et al. · 2005 [cited by applicant]
US 20050260716A1 · Moore et al. · 2005 [cited by applicant]
US 20060034826A1 · Carreno et al. · 2006 [cited by applicant]
US 20060068386A1 · Al. · 2006 [cited by applicant]
US 20060084794A1 · Rosen et al. · 2006 [cited by applicant]
US 20060110383A1 · Honjo et al. · 2006 [cited by applicant]
US 20060159685A1 · Mikesell et al. · 2006 [cited by applicant]
US 20060223088A1 · Rosen et al. · 2006 [cited by applicant]
US 20060276422A1 · Usman et al. · 2006 [cited by applicant]
US 20070037206A1 · Rosen et al. · 2007 [cited by applicant]
US 20070041963A1 · Rosen et al. · 2007 [cited by applicant]
US 20070065427A1 · Freeman et al. · 2007 [cited by applicant]
US 20070092504A1 · Carreno et al. · 2007 [cited by applicant]
US 20070099833A1 · Rosen et al. · 2007 [cited by applicant]
US 20070122378A1 · Freeman et al. · 2007 [cited by applicant]
US 20070224663A1 · Rosen et al. · 2007 [cited by applicant]
US 20070231344A1 · Leadbetter et al. · 2007 [cited by applicant]
US 20080025979A1 · Honjo et al. · 2008 [cited by applicant]
US 20080118511A1 · Freeman et al. · 2008 [cited by applicant]
US 20080226662A1 · Pardoll et al. · 2008 [cited by applicant]
US 20080241175A1 · Pardoll et al. · 2008 [cited by applicant]
US 20090012292A1 · Chen · 2009 [cited by applicant]
US 20090068193A1 · Chen et al. · 2009 [cited by applicant]
US 20090075338A1 · Moore et al. · 2009 [cited by applicant]
US 20090176317A1 · Kwon et al. · 2009 [cited by applicant]
US 20090215084A1 · Kwon et al. · 2009 [cited by applicant]
US 20090269783A1 · Coyle et al. · 2009 [cited by applicant]
US 20090304711A1 · Pardoll et al. · 2009 [cited by applicant]
US 20100015642A1 · Kwon et al. · 2010 [cited by applicant]
US 20100092470A1 · Bhatt et al. · 2010 [cited by applicant]
US 20100285039A1 · Chen · 2010 [cited by applicant]
US 20110020325A1 · Kwon et al. · 2011 [cited by applicant]
US 20110010409A1 · Strome et al. · 2011 [cited by applicant]
US 20120065374A1 · Pardoll et al. · 2012 [cited by applicant]
US 20120065385A1 · Pardoll et al. · 2012 [cited by applicant]
US 20120225043A1 · Chen et al. · 2012 [cited by applicant]
US 20130058936A1 · Bruenker et al. · 2013 [cited by applicant]
US 20130123566A1 · Lupold et al. · 2013 [cited by applicant]
US 20130251736A1 · Kwon et al. · 2013 [cited by applicant]
US 20130273656A1 · Hendrickson · 2013 [cited by applicant]
US 20140031260A1 · O'Donnell et al. · 2014 [cited by applicant]
US 20140242080A1 · Roche · 2014 [cited by applicant]
US 20140271674A1 · Dong · 2014 [cited by applicant]
US 20140329248A1 · Kwon et al. · 2014 [cited by applicant]
US 20140335541A1 · Kwon et al. · 2014 [cited by applicant]
US 20150111232A1 · Kwon et al. · 2015 [cited by applicant]
US 20150203580A1 · Papadopoulos et al. · 2015 [cited by applicant]
US 20150273033A1 · Bosch et al. · 2015 [cited by applicant]
US 20150337048A1 · Stull et al. · 2015 [cited by applicant]
US 20160045581A1 · Ince et al. · 2016 [cited by applicant]
US 20160051651A1 · Brogdon et al. · 2016 [cited by applicant]
US 20160068601A1 · Brogdon et al. · 2016 [cited by applicant]
US 20160153996A1 · Kwon et al. · 2016 [cited by applicant]
US 20160154000A1 · Kwon · 2016 [cited by applicant]
US 20160176967A1 · Dong et al. · 2016 [cited by applicant]
US 20160237407A1 · Wagner et al. · 2016 [cited by applicant]
US 20160251437A1 · Dong et al. · 2016 [cited by applicant]
US 20170089918A1 · Dong · 2017 [cited by applicant]
US 20170121416A1 · Stull et al. · 2017 [cited by applicant]
US 20170173030A1 · Dong · 2017 [cited by applicant]
US 20170274095A1 · Meyer et al. · 2017 [cited by applicant]
US 20170275375A1 · Rossi et al. · 2017 [cited by applicant]
US 20170327590A1 · Lowy et al. · 2017 [cited by applicant]
US 20170363634A1 · Kwon · 2017 [cited by applicant]
US 20180139940A1 · Macdonald et al. · 2018 [cited by applicant]
US 20180154183A1 · Sahadevan · 2018 [cited by applicant]
US 20190038671A1 · Fan et al. · 2019 [cited by applicant]
US 20190292539A1 · Fulga et al. · 2019 [cited by applicant]
US 20190298774A1 · Lin et al. · 2019 [cited by applicant]
US 20190315869A1 · Dong · 2019 [cited by applicant]
US 20190361033A1 · Dong · 2019 [cited by applicant]
US 20200054673A1 · Ports et al. · 2020 [cited by applicant]
US 20200061077A1 · Dong · 2020 [cited by applicant]
US 20200147117A1 · Ben Yakar et al. · 2020 [cited by applicant]
US 20200190196A1 · Dong · 2020 [cited by applicant]
US 20200270355A1 · Faustman · 2020 [cited by applicant]
US 20200271656A1 · Cumba-Garcia et al. · 2020 [cited by applicant]
US 20200338112A1 · Lou et al. · 2020 [cited by applicant]
US 20210003556A1 · Dong · 2021 [cited by applicant]
US 20210145830A1 · Kenderian et al. · 2021 [cited by applicant]
US 20210145881A1 · Kenderian et al. · 2021 [cited by applicant]
US 20210355190A1 · Kenderian et al. · 2021 [cited by applicant]
US 20220041686A1 · Mackall et al. · 2022 [cited by applicant]
US 20220401488A1 · Kenderian et al. · 2022 [cited by applicant]
US 20230045174A1 · Rezvani et al. · 2023 [cited by applicant]
CN 103641917 · 2014 [cited by applicant]
CN 105814074 · 2016 [cited by applicant]
CN 107406517 · 2017 [cited by applicant]
CN 107849112 · 2018 [cited by applicant]
EP 1074617 · 2001 [cited by applicant]
EP 1537878 · 2005 [cited by applicant]
EP 2997141 · 2016 [cited by applicant]
EP 3130350 · 2017 [cited by applicant]
EP 2968415 · 2019 [cited by applicant]
EP 3964265 · 2022 [cited by applicant]
WO WO1990007861 · 1990 [cited by applicant]
WO WO1991010741 · 1991 [cited by applicant]
WO WO1991011465 · 1991 [cited by applicant]
WO WO1991017271 · 1991 [cited by applicant]
WO WO1992000092 · 1992 [cited by applicant]
WO WO1992001047 · 1992 [cited by applicant]
WO WO1992020791 · 1992 [cited by applicant]
WO WO1993001222 · 1993 [cited by applicant]
WO WO1995005464 · 1995 [cited by applicant]
WO WO1995007707 · 1995 [cited by applicant]
WO WO1996029348 · 1996 [cited by applicant]
WO WO1997017613 · 1997 [cited by applicant]
WO WO1997017614 · 1997 [cited by applicant]
WO WO1997024447 · 1997 [cited by applicant]
WO WO1998016249 · 1998 [cited by applicant]
WO WO1998023635 · 1998 [cited by applicant]
WO WO1998033914 · 1998 [cited by applicant]
WO WO1998036096 · 1998 [cited by applicant]
WO WO1999036093 · 1999 [cited by applicant]
WO WO1999064597 · 1999 [cited by applicant]
WO WO2000026342 · 2000 [cited by applicant]
WO WO2000029445 · 2000 [cited by applicant]
WO WO2000029582 · 2000 [cited by applicant]
WO WO2000041508 · 2000 [cited by applicant]
WO WO2000055375 · 2000 [cited by applicant]
WO WO2000061612 · 2000 [cited by applicant]
WO WO2001034629 · 2001 [cited by applicant]
WO WO2001062905 · 2001 [cited by applicant]
WO WO2001070979 · 2001 [cited by applicant]
WO WO2001083750 · 2001 [cited by applicant]
WO WO2001094413 · 2001 [cited by applicant]
WO WO2002000692 · 2002 [cited by applicant]
WO WO2002000730 · 2002 [cited by applicant]
WO WO2002002587 · 2002 [cited by applicant]
WO WO2002002891 · 2002 [cited by applicant]
WO WO2002008279 · 2002 [cited by applicant]
WO WO2002078731 · 2002 [cited by applicant]
WO WO2002024891 · 2002 [cited by applicant]
WO WO2002046449 · 2002 [cited by applicant]
WO WO2002057453 · 2002 [cited by applicant]
WO WO2002079474 · 2002 [cited by applicant]
WO WO2002081731 · 2002 [cited by applicant]
WO WO2002086083 · 2002 [cited by applicant]
WO WO2003006632 · 2003 [cited by applicant]
WO WO2003008583 · 2003 [cited by applicant]
WO WO2003049755 · 2003 [cited by applicant]
WO WO2004085418 · 2004 [cited by applicant]
WO WO2006042237 · 2006 [cited by applicant]
WO WO2006050172 · 2006 [cited by applicant]
WO WO2006133396 · 2006 [cited by applicant]
WO WO2008037080 · 2008 [cited by applicant]
WO WO2008083174 · 2008 [cited by applicant]
WO WO2009023566 · 2009 [cited by applicant]
WO WO2009029342 · 2009 [cited by applicant]
WO WO2009114110 · 2009 [cited by applicant]
WO WO2010027423 · 2010 [cited by applicant]
WO WO2010027827 · 2010 [cited by applicant]
WO WO2010027828 · 2010 [cited by applicant]
WO WO2010098788 · 2010 [cited by applicant]
WO WO2011066342 · 2011 [cited by applicant]
WO WO2011066389 · 2011 [cited by applicant]
WO WO2011072246 · 2011 [cited by applicant]
WO WO2013003112 · 2013 [cited by applicant]
WO WO2013019906 · 2013 [cited by applicant]
WO WO2013090552 · 2013 [cited by applicant]
WO WO2013132044 · 2013 [cited by applicant]
WO WO2014110045 · 2014 [cited by applicant]
WO WO2014144666 · 2014 [cited by applicant]
WO WO2014163684 · 2014 [cited by applicant]
WO WO2014184143 · 2014 [cited by applicant]
WO WO2015049280 · 2015 [cited by applicant]
WO WO2015050663 · 2015 [cited by applicant]
WO WO2015061668 · 2015 [cited by applicant]
WO WO2015066262 · 2015 [cited by applicant]
WO WO2015142314 · 2015 [cited by applicant]
WO WO2015157252 · 2015 [cited by applicant]
WO WO2015179654 · 2015 [cited by applicant]
WO WO2016014148 · 2016 [cited by applicant]
WO WO2016014576 · 2016 [cited by applicant]
WO WO2016018920 · 2016 [cited by applicant]
WO WO2016120219 · 2016 [cited by applicant]
WO WO2016164731 · 2016 [cited by applicant]
WO WO2016201394 · 2016 [cited by applicant]
WO WO2017023803 · 2017 [cited by applicant]
WO WO2017066561 · 2017 [cited by applicant]
WO WO2017075389 · 2017 [cited by applicant]
WO WO2017091546 · 2017 [cited by applicant]
WO WO2017100587 · 2017 [cited by applicant]
WO WO2017143094 · 2017 [cited by applicant]
WO WO2017172981 · 2017 [cited by applicant]
WO WO2017173360 · 2017 [cited by applicant]
WO WO2017177179 · 2017 [cited by applicant]
WO WO2017220704 · 2017 [cited by applicant]
WO WO2017222593 · 2017 [cited by applicant]
WO WO2018005712 · 2018 [cited by applicant]
WO WO2018045069 · 2018 [cited by applicant]
WO WO2018073391 · 2018 [cited by applicant]
WO WO2018195339 · 2018 [cited by applicant]
WO WO2019036724 · 2019 [cited by applicant]
WO WO2019108756 · 2019 [cited by applicant]
WO WO2019133793 · 2019 [cited by applicant]
WO WO2019178334 · 2019 [cited by applicant]
WO WO2019195142 · 2019 [cited by applicant]
WO WO2019217423 · 2019 [cited by applicant]
WO WO2019232370 · 2019 [cited by applicant]
WO WO2020018620 · 2020 [cited by applicant]
WO WO2021092577 · 2021 [cited by applicant]
WO WO2022236049 · 2022 [cited by applicant]
WO WO2022236142 · 2022 [cited by applicant]
WO WO2022266396 · 2022 [cited by applicant]
Aldous et al. Bioorganic & Medicinal Chemistry 26 (2018) 2842-2849. [cited by examiner]
Rusch et al. Arch. Immunol. Ther. Exp. (2018) 66: 89-96. [cited by examiner]
Weitzel et al., “microRNA 184 regulates expression of NFAT1 in umbilical cord blood CD4+T cells,” Blood, Jun. 25, 2009, 113(26):6648-6657. [cited by applicant]
Grupp et al., “T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adult… [cited by applicant]
Boyiadzis et al., “The emerging roles of tumor-derived exosomes in hematological malignancies,” Leukemia, Mar. 21, 2017, 31(6):1259-1268. [cited by applicant]
Corcoran et al., “Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes,” PLoS One, Dec. 10, 2012, 7(12):e50999, 12 pages. [cited by applicant]
EP Extended Search Report in European Appln. No. 19880748.9, dated Jun. 29, 2022, 9 pages. [cited by applicant]
Liu, “Differential Expression of Cell Surface Molecules in Prostate Cancer Cells,” Cancer Research, Jul. 1, 200, 60:3429-3434. [cited by applicant]
Oksvold et al., “Expression of B-Cell Surface Antigens in Subpopulations of Exosomes Released From B-Cell Lymphoma Cells,” Clin. Therapeutics, Jun. 18, 2014, 36(6):847-862.e1. [cited by applicant]
Agarwal et al., “In vivo generated human Car T cells eradicate tumor cells,” Oncoimmunology, Oct. 10, 2019, 8(12):E1671761, 7 pages. [cited by applicant]
Bender et al., “Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell Attachment,” PLOS Pathogens, Jun. 9, 2016, 12(6):E1005641, 28 page… [cited by applicant]
Buchholz et al., “Surface-Engineered Viral Vectors for Selective and Cell Type-Specific Gene Delivery,” Trends in Biotechnology, Dec. 2015, 33(12):777-790. [cited by applicant]
Frank et al., “Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes,” Mol. Ther. Methods Clin. Development, Mar. 2019, 12:19-31. [cited by applicant]
Pfeiffer et al., “In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome,” EMBO Mol. Medicine, Sep. 17, 2018, 10(11):E9158, 11 pages. [cited by applicant]
Zhou et al., “Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors,” J. Immunology, Jul. 31, 2015, 195(5):2493-2501. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2019/059113, dated Apr. 27, 2021, 8 pages. [cited by applicant]
Adusumilli et al., “Regional delivery of mesothelin-targeted Car T cell therapy generates potent and long-lasting CD4-dependent tumor immunity,” Sci. Transl. Medicine, Nov. 5, 2014, 6(261):261ra151, 15 pages. [cited by applicant]
Agace et al., “T-lymphocyte-epithelial-cell interactions: integrin αE(CD103)β7, LEEP-CAM and chemokines,” Curr. Opin. Cell Biology, Oct. 1, 2000, 12(5):563-568. [cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Research, Sep. 1, 1997, 25(17):3389-3402. [cited by applicant]
An et al., “Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells,” Mol. Pharmaceutics, Sep. 5, 2018, 15(10):4577-4588. [cited by applicant]
Ao et al., “Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer,” J. Immunotherapy, Oct. 2019, 42(8):284-296. [cited by applicant]
Belov et al., “Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples,” J. Extracell. Vesicles, Apr. 15, 2016, 5:25355, 12 pages. [cited by applicant]
Bielamowics et al., “Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma,” Neuro-Oncology, Sep. 16, 2017, 20(4):506-518. [cited by applicant]
Blat et al., “Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells,” Mol. Therapy, May 2014, 22(5):1018-1028. [cited by applicant]
Caivano et al., “Extracellular Vesicles In Hematological Malignancies: From Biology to Therapy,” Int. J. Mol. Sciences, Jun. 2, 2017, 18(6):1183, 23 pages. [cited by applicant]
Caruso et al., “Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity,” Cancer Research, Sep. 2015, 75(17):3505-3518. [cited by applicant]
Chi et al., “Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12,” Cancer Medicine, Jun. 25, 2019, 8(10):4753-47… [cited by applicant]
Chu et al., “CSI-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma,” Leukemia, Apr. 2014, 28(4):917-927. [cited by applicant]
ClinicalTrials.gov [online], “First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors,” NCT02729298, last updated Jan. 25, 2021, retrieved on Apr. 23, 2021, retrieve… [cited by applicant]
ClinicalTrials.gov [online], “Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL,” NCT03572634, last updated Feb. 2, 2021, retrieved on Apr. 23, 2021, retrieved from URL<http… [cited by applicant]
Cohen et al., “B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma,” J. Clin. Investigation, Mar. 21, 2019, 129(6):2210-2221. [cited by applicant]
Dahlhamer et al., “Prevalence of Inflammatory Bowel Disease Among Adults Aged ≤18 Years—United States, 2015,” MMWR Morb. Mortal. Wkly Report, Oct. 28, 2016, 65(42):1166-1169. [cited by applicant]
Dimopoulos et al., “Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma,” N. Engl. J. Medicine, Nov. 8, 2018, 379(19):1811-1822. [cited by applicant]
Forsberg et al., “HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy—Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice,” Cancer Research, Mar. 2019, 79(5):899-904. [cited by applicant]
Forsman et al., “Size Matters: Identification of Larger Size CD19 Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia That Inhibit Chimeric Antigen Receptor T Cell Functions,” Blood, Nov. 29, 2018, 132(S1):1… [cited by applicant]
Fry et al., “CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy,” Nat. Medicine, Nov. 20, 2017, 24(1):20-28. [cited by applicant]
GenBank Accession No. AAH32229.1, “AXL receptor tyrosine kinase [ [cited by applicant]
GenBank Accession No. EAW57023.1, “AXL receptor tyrosine kinase, isoform CRA_b [ [cited by applicant]
GenBank Accession No. M76125.1, “Human tyrosine kinase receptor (axl) mRNA, complete eds,” dated Jan. 14, 1995, 2 pages. [cited by applicant]
GenBank Accession No. NM_001699.5, “ [cited by applicant]
Gill et al., “Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells,” Blood, Apr. 10, 2014, 123(15):2343-2354. [cited by applicant]
Guo et al., “Axl Inhibition Induces The Antitumor Immune Response Which Can Be Further Potentiated By PD-1 Blockade in The Mouse Cancer Models,” Oncotarget, Sep. 21, 2017, 8(52):89761-8977. [cited by applicant]
Haas et al., “Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers,” Mol. Therapy, Nov. 6, 2019, 27(11):1919-1929. [cited by applicant]
Hoffmann et al., “Only the CD45RA+ subpopulation of CD4+ CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion,” Blood, Dec. 15, 2006, 108(13):4260-4267. [cited by applicant]
Jacobsohn et al., “Acute graft versus host disease,” Orphanet. J. Rare Diseases, Sep. 4, 2007, 2:35, 9 pages. [cited by applicant]
Jiang et al., “Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell,” Cancer Immunol. Research, Nov. 2018, 6(11):1314-1326. [cited by applicant]
Kantarjian et al., “Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia,” N. Engl. J. Medicine, Aug. 25, 2016, 375(8):740-753. [cited by applicant]